Get started
Capricor Therapeutics, Inc.Capricor Therapeutics, Inc.Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

CAPR chart


Full chart

CAPR upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪513.86 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.20 USD
Net income (FY)
‪−40.47 M‬ USD
Revenue (FY)
‪22.27 M‬ USD
Shares float
‪40.12 M‬
Beta (1Y)
2.17

Employees


Employees (FY)
160
Change (1Y)
+58 +56.86%
Revenue / Employee (1Y)
‪139.19 K‬ USD
Net income / Employee (1Y)
‪−252.92 K‬ USD

About Capricor Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Linda Marbán
Website
capricor.com
Headquarters
San Diego
Founded
1996
FIGI
BBG000DZMK99
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CAPR news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as CAPR.

Frequently Asked Questions


The current price of CAPR is 11.25 USD — it has increased by 16.70% in the past 24 hours. Watch Capricor Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Capricor Therapeutics, Inc. stocks are traded under the ticker CAPR.
CAPR stock has risen by 21.62% compared to the previous week, the month change is a −12.66% fall, over the last year Capricor Therapeutics, Inc. has showed a 88.13% increase.
We've gathered analysts' opinions on Capricor Therapeutics, Inc. future price: according to them, CAPR price has a max estimate of 77.00 USD and a min estimate of 25.00 USD. Watch CAPR chart and read a more detailed Capricor Therapeutics, Inc. stock forecast: see what analysts think of Capricor Therapeutics, Inc. and suggest that you do with its stocks.
CAPR reached its all-time high on Dec 17, 2002 with the price of 8,000.00 USD, and its all-time low was 0.88 USD and was reached on Mar 12, 2020. View more price dynamics on CAPR chart.
See other stocks reaching their highest and lowest prices.
CAPR stock is 16.47% volatile and has beta coefficient of 2.17. Track Capricor Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Capricor Therapeutics, Inc. there?
Today Capricor Therapeutics, Inc. has the market capitalization of ‪513.86 M‬, it has increased by 4.47% over the last week.
Yes, you can track Capricor Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Capricor Therapeutics, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
CAPR earnings for the last quarter are −0.16 USD per share, whereas the estimation was −0.17 USD resulting in a 5.88% surprise. The estimated earnings for the next quarter are −0.32 USD per share. See more details about Capricor Therapeutics, Inc. earnings.
Capricor Therapeutics, Inc. revenue for the last quarter amounts to ‪11.13 M‬ USD, despite the estimated figure of ‪3.52 M‬ USD. In the next quarter, revenue is expected to reach ‪3.16 M‬ USD.
CAPR net income for the last quarter is ‪−7.12 M‬ USD, while the quarter before that showed ‪−12.56 M‬ USD of net income which accounts for 43.32% change. Track more Capricor Therapeutics, Inc. financial stats to get the full picture.
No, CAPR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 21, 2025, the company has 160 employees. See our rating of the largest employees — is Capricor Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Capricor Therapeutics, Inc. EBITDA is ‪−41.14 M‬ USD, and current EBITDA margin is −184.73%. See more stats in Capricor Therapeutics, Inc. financial statements.
Like other stocks, CAPR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Capricor Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Capricor Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Capricor Therapeutics, Inc. stock shows the neutral signal. See more of Capricor Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.